Recent Activity

Loading...

CYBN

Cybin, Inc. · AMEX

Performance

+3.57%

1W

-14.73%

1M

+12.47%

3M

-28.27%

6M

-11.59%

YTD

+20.03%

1Y

Profile

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

Technical Analysis of CYBN 2024-05-10

Overview:

In analyzing the technical indicators for CYBN over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for potential inves...

See more ...

Recent News & Updates